David Scheer

Chairman of the Board

Mr. Scheer was involved in the founding and had been a member of the Boards of Directors of ViroPharma, Inc.(NASDAQ, “VPHM”), OraPharma, Inc. (acquired by Johnson & Johnson in 2003), and Esperion Therapeutics, Inc. (of which he was Chairman, acquired by Pfizer in 2004). His other current board relationships include Tengion, Inc. (of which he is Chairman, NASDAQ, “TNGN”), Aegerion Pharmaceuticals, Inc. (of which he is Chairman, NASDAQ, “AEGR”), Optherion, Inc. (of which he is Chairman), and Axerion Therapeutics, Inc. (of which he is Chairman). From 1991 through 1999, he was affiliated with the health care investing team at Oak Investment Partners. Mr. Scheer has also led or played a significant role in a series of transactions involving corporate alliances, licensing arrangements, divestments, acquisitions and mergers in the life sciences. He has served as a member of the Leadership Council of the Harvard School of Public Health, and as a member of the Advisory Committee to the Harvard Malaria Initiative. He has helped to launch, and served as Chair of the Executive Committee for “The Unfinished Agenda in Infectious Diseases”, an initiative at the Harvard School of Public Health focusing on the neglected diseases. He has also been a member of the Global Advisory Council for AIDS@30, an initiative at Harvard, and the Chair of the Strategic Advisory Committee for the Global Task Force for Expanding Cancer Care and Control in the Developing World, another Harvard-affiliated initiative. He has also been a member of the Board of Trustees, and most recently Vice-Chair for the Long Wharf Theatre, in New Haven, CT. In 2007, he was awarded the Atlas Award for Venture Capital from the Connecticut Union for Research Excellence (CURE, of which he also serves as a member of the Board), and in 2009, he received the Venture Capital Leadership Award from the Connecticut Venture Group. He received his A.B. cum laude from Harvard College, and an M.S. from Yale University.